Cost-effectiveness data for cancer treatment are needed from sub-Saharan Africa, where diffuse large B-cell lymphoma (DLBCL) is a common, curable cancer. In high-income countries, the standard of care for DLBCL is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) ...
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial The Lancet Oncology, Volume 20, Issue 5, May 2019, Pages 649-662 Andrew Davies, Thomas E Cummin, Sharon Barrans, Tom Maishman...
目的:探讨Zeste基因增强子(enhancer of zeste homolog 2,EZH2)对弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)RCHOP方案治疗的效果的预测价值.方法:纳入2017年1月至2018年5月南华大学附属第二医院80例接受RCHOP方案治疗的DLBCL患者,分析患者EZH2表达情况与治疗效果的关系,绘制EZH2预测治疗效果的ROC曲线,并...
Follicular lymphoma (FL), a common B-cell non-Hodgkin’s lymphoma (NHL) subtype, accounts for about 70% of indolent lymphomas [1, 2]. The R-CHOP regime (rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone) serves as the first-line treatment option for the majority...
Dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA.R-EPOCH) is used for upfront treatment of high-risk diffuse large B cell lymphoma (DLBCL). In this study, we compared the outcomes in patients with high-ris
Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-cell lymphoma (DLBCL). The aim of this analysis is to report long-term outcome and toxicities in newly diagnosed DLBCL patients who received
(PFS) for newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with the addition of lenalidomide (Revlimid) to R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone), based on data reported during the International Conference on Malignant Lymphom...
Andre Goy, MD, MS:It is a challenge. There have been repeated trials where the phase II was very promising, and then the phase III setting the selection process... I would say that for our audience, the 6 cycles of R-CHOP for basic large cell lymphoma still remains. We’ll go into...
Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL). However, the schedule for rituximab administration has not been optimized. To compare standard R-CHOP with CHOP plus dose-dense weekly rituximab (RW...
Based on these findings and mode of action, venetoclax may have potential as a chemosensitizing agent. The CAVALLI study explored the safety and efficacy of combining venetoclax with R-CHOP or G-CHOP chemotherapy in patients with NHL. Here, we report results of the phase 1b part of CAVALLI....